• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
AADAT-Driven Metabolic Control of Malate and CoQ Shapes Immune Evasion in Triple-Negative Breast Cancer.AADAT驱动的苹果酸和辅酶Q代谢控制塑造三阴性乳腺癌的免疫逃逸
bioRxiv. 2026 Jan 30:2026.01.28.702389. doi: 10.64898/2026.01.28.702389.
2
SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer.SMC4通过抑制内源性干扰素信号传导和上调三阴性乳腺癌中PD-L1的表达来促进免疫逃逸。
Int Immunopharmacol. 2025 Dec 3;166:115580. doi: 10.1016/j.intimp.2025.115580. Epub 2025 Sep 20.
3
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.基于生物纳米颗粒的疫苗和检查点阻断刺激的适应性抗肿瘤免疫反应。
J Exp Clin Cancer Res. 2022 Apr 8;41(1):132. doi: 10.1186/s13046-022-02307-3.
4
Recent progress in immune evasion mechanisms of triple-negative breast cancer.三阴性乳腺癌免疫逃逸机制的最新进展
J Transl Med. 2025 Nov 18;23(1):1314. doi: 10.1186/s12967-025-07370-w.
5
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.适配子靶向治疗增强三阴性乳腺癌的免疫检查点阻断。
J Exp Clin Cancer Res. 2020 Sep 7;39(1):180. doi: 10.1186/s13046-020-01694-9.
6
Targeting CREB1/p300-mediated RGS1 expression in tumor-associated macrophages improves the efficacy of anti-PD-1 therapy in triple-negative breast cancer.
Biochem Pharmacol. 2025 Dec;242(Pt 4):117395. doi: 10.1016/j.bcp.2025.117395. Epub 2025 Oct 3.
7
Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer.肿瘤坏死因子受体 2 通过调节乳腺癌化疗耐药中的糖酵解促进内皮细胞介导的 CD8+T 细胞抑制。
J Transl Med. 2024 Jul 20;22(1):672. doi: 10.1186/s12967-024-05472-5.
8
Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD pathway.氨基酸转运体LAT1(SLC7A5)通过L-色氨酸/QPRT/烟酰胺腺嘌呤二核苷酸途径促进三阴性乳腺癌进展中的代谢重塑。
J Exp Clin Cancer Res. 2025 Jul 3;44(1):190. doi: 10.1186/s13046-025-03446-z.
9
Nuclear PD-L1 drives IFN-γ-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E.
Breast Cancer Res. 2025 Dec 12;28(1):14. doi: 10.1186/s13058-025-02193-5.
10
ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.ALG3 通过调节 TNBC 中 PD-L1 N-连接糖基化来预测不良预后并增加对抗 PD-1 治疗的耐药性。
Int Immunopharmacol. 2024 Oct 25;140:112875. doi: 10.1016/j.intimp.2024.112875. Epub 2024 Aug 9.

AADAT驱动的苹果酸和辅酶Q代谢控制塑造三阴性乳腺癌的免疫逃逸

AADAT-Driven Metabolic Control of Malate and CoQ Shapes Immune Evasion in Triple-Negative Breast Cancer.

作者信息

Chatterjee Megha, Gu Franklin, Samanta Susmita, Rasaily Uttam, Thota Sai Manohar, Varghese Dana, Qiu Yunping, Fordwuo Lynette Ewura Esi, Villanueva Hugo, McKenna Mary Kathryn, Park Jun Hyoung, Zhang Weijie, Tian Lin, Yu Liqun, Piyarathna Badrajee, Gao Yang, Simons Brian Wesley, Jung Sung Yun, Karanam Balasubramanyam, Putluri Vasanta, Chandandeep Nagi, Mohamed Nada, Asirvatham Jaya Ruth, Jebakumar Deborah, Rao Arundati, Gutierrez Carolina, Omilian Angela R, Morrison Carl, Das Gokul M, Ambrosone Christine, Seeley Erin H, Kaipparettu Benny Abraham, Kurland Irwin J, Putluri Nagireddy, Elkhanany Ahmed, Davis Andrew A, Zhu Qian, Zhang Xiang H-F, Sreekumar Arun

机构信息

Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.

Verna & Marrs McLean Dept. of Biochemistry & Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

bioRxiv. 2026 Jan 30:2026.01.28.702389. doi: 10.64898/2026.01.28.702389.

DOI:10.64898/2026.01.28.702389
PMID:41659489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12874059/
Abstract

Compared to other subtypes of breast cancer, triple-negative breast cancers (TNBC) have fewer treatment options and exhibit a worse prognosis. Through integrated transcriptomic, metabolomic, immunohistochemical, spatial, and clinical analyses, we identify the mitochondrial enzyme, α-aminoadipate aminotransferase (AADAT) as a previously unrecognized metabolic immune checkpoint in TNBC. mRNA and protein were significantly upregulated in human TNBC, and high AADAT expression was associated with reduced intra-tumoral CD8 T-cell density and inferior survival. Genetic silencing of in orthotopic murine TNBC models curtailed primary tumor growth and distant metastasis in a CD8 T-cell-dependent manner, enhanced effector T-cell activation, and sensitized tumors to dual PD-1/CTLA-4 blockade. Mechanistically, unbiased metabolomics showed increased malate levels after knockdown. Additionally, 4-hydroxyphenylpyruvate, an essential precursor for coenzyme Q(CoQ) biosynthesis, decreased following knockdown, suggesting an impaired mitochondrial electron transport chain. CoQ supplementation restored metabolic balance and reversed malate accumulation caused by knockdown, indicating that AADAT helps maintain CoQ-supported redox homeostasis, thereby preventing malate buildup and export. Notably, malate addition directly boosted CD8 T-cell oxidative metabolism, increased the NAD/NADH ratio and reactive oxygen species, and augmented TNF-α and IFN-γ production. In vivo, malate supplementation in drinking water phenocopied AADAT knockdown, restored the response to paclitaxel plus anti-PD-1 therapy in multiple independent syngeneic TNBC models with de novo or acquired resistance to immunotherapy, reduced tumor burden, and prolonged survival. In patient cohorts, higher spatially clustered intra-tumoral malate is associated with co-localization of functional CD8 T cells, decreased exhausted T-cell neighborhoods, and superior post-chemotherapy outcomes. These data position AADAT as a central metabolic orchestrator of immune escape in TNBC and nominate oral malate as a readily translatable adjuvant to reverse chemo-immunotherapy resistance in TNBC.

摘要

与其他亚型的乳腺癌相比,三阴性乳腺癌(TNBC)的治疗选择较少,预后较差。通过整合转录组学、代谢组学、免疫组织化学、空间分析和临床分析,我们确定线粒体酶α-氨基己二酸转氨酶(AADAT)是TNBC中一种先前未被认识的代谢免疫检查点。AADAT的mRNA和蛋白在人类TNBC中显著上调,高AADAT表达与肿瘤内CD8 T细胞密度降低和较差的生存率相关。在原位小鼠TNBC模型中,AADAT基因沉默以CD8 T细胞依赖的方式抑制原发性肿瘤生长和远处转移,增强效应T细胞活化,并使肿瘤对双重PD-1/CTLA-4阻断敏感。从机制上讲,非靶向代谢组学显示AADAT基因敲低后苹果酸水平升高。此外,辅酶Q(CoQ)生物合成的必需前体4-羟基苯丙酮酸在AADAT基因敲低后减少,表明线粒体电子传递链受损。补充CoQ可恢复代谢平衡,并逆转AADAT基因敲低导致的苹果酸积累,表明AADAT有助于维持CoQ支持的氧化还原稳态,从而防止苹果酸积累和输出。值得注意的是,添加苹果酸直接促进CD8 T细胞的氧化代谢,增加NAD/NADH比值和活性氧,并增强TNF-α和IFN-γ的产生。在体内,饮用水中补充苹果酸模拟了AADAT基因敲低的效果,恢复了多个对免疫疗法具有原发性或获得性耐药性的独立同基因TNBC模型对紫杉醇加抗PD-1疗法的反应,减轻了肿瘤负担,并延长了生存期。在患者队列中,肿瘤内空间聚集的苹果酸水平较高与功能性CD8 T细胞的共定位、耗尽T细胞区域减少以及化疗后更好的结果相关。这些数据将AADAT定位为TNBC免疫逃逸的核心代谢协调因子,并将口服苹果酸提名为一种易于转化的佐剂,以逆转TNBC中的化学免疫疗法耐药性。